Hypothesis

Age‑associated elevation of plasma von Willebrand factor (vWF) and Factor VIII (FVIII) is not merely a deleterious side‑effect of aging but an evolved mechanism that enhances clearance of senescent cells via platelet‑leukocyte aggregates, thereby conferring early‑life fitness benefits at the cost of late‑life thrombotic pathology.

Mechanistic rationale

1. Senescent cell clearance – Senescent cells expose phosphatidylserine and express adhesion molecules (e.g., ICAM‑1) that bind activated platelets and leukocytes. Elevated vWF/FVIII promotes platelet adhesion under shear and stabilizes platelet‑leukocyte aggregates, which have been shown to phagocytose senescent cells in the liver and spleen [6].
2. Kin‑selected benefit – Efficient removal of senescent cells reduces the senescence‑associated secretory phenotype (SASP), preserving tissue function and reproductive capacity in young adults. This improves individual fitness and, by extending the period of effective parental care, increases inclusive fitness of kin.
3. Trade‑off – The same pro‑aggregatory milieu that aids senescent cell clearance also raises thrombin generation and microvascular thrombosis, which becomes pathogenic once reproductive selection wanes, manifesting as age‑related cardiovascular and cerebrovascular disease [1,2].
4. Evolutionary signature – The transcriptional programs driving megakaryocytic bias in aged hematopoietic stem cells are conserved between humans and mice [4], suggesting selective retention of a coagulation‑senescence axis.

Testable predictions

• Prediction 1: In young adult mice, genetic or antibody‑mediated reduction of vWF/FVIII will decrease platelet‑leukocyte aggregate formation, leading to a measurable increase in hepatic senescent cell burden (β‑galactosidase+, p16^Ink4a^) and SASP cytokines (IL‑6, IL‑1β) without altering baseline coagulation times.
• Prediction 2: Despite lower thrombosis risk, these mice will exhibit earlier onset of age‑related functional decline (e.g., reduced grip strength, impaired glucose tolerance) and shortened median lifespan compared with controls.
• Prediction 3: Transfusion of plasma from old mice (high vWF/FVIII) into young vWF‑deficient mice will rescue senescent cell clearance and extend healthspan, an effect blocked by anti‑P‑selectin antibodies that disrupt platelet‑leukocyte aggregates.
• Prediction 4: Pharmacologic inhibition of vWF (e.g., caplacizumab) in midlife primates will increase circulating senescent cell markers and reduce healthspan biomarkers, even as thrombotic events decline.

Falsifiability

If reducing vWF/FVIII fails to increase senescent cell load or does not accelerate functional decline, the hypothesis that hypercoagulability serves a senescent‑cell‑clearance function would be falsified. Conversely, demonstrating that enhancing vWF/FVIII‑mediated aggregate formation specifically lowers senescent cell burden without worsening thrombosis would support the evolutionary trade‑off model.

Broader implications

Longevity strategies that blunt coagulation may need to preserve or mimic the senescent‑cell‑clearance arm—perhaps by targeting vWF’s adhesive domains while sparing its pro‑coagulant activity—or combine senolytics with mild pro‑aggregatory agents to retain the kinetic advantage evolution built into our blood.

References [1] https://pubmed.ncbi.nlm.nih.gov/33221577/ [2] https://pmc.ncbi.nlm.nih.gov/articles/PMC442420/ [3] https://pubmed.ncbi.nlm.nih.gov/25099191/ [4] https://doi.org/10.1371/journal.pone.0158369 [5] https://journals.plos.org/ploscompbiol/article?id=10.1371%2Fjournal.pcbi.1007162 [6] https://www.ahajournals.org/doi/10.1161/ATVBAHA.123.319255